...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Trial

The extension,new trial is listed on Clinical trials.gov.As I see it they have allowed those patients that benefited from the combo by invitation to stay on the combo till 2022.This may not be a Trial per se but there must be a moral obligation to have those that want to to receive the drug

Share
New Message
Please login to post a reply